雷递网 雷建平 5月14日诺诚健华医药有限公司(公司代码:688428,公司简称:诺诚健华)日前发布截至2025年第一季度的财报。年报显示,诺诚健华2025年第一季度营收为3.81亿元,较上年同期的1.66亿元增长129.9%。诺诚健华称,本期营业收入大幅增加,一方面系奥布替尼销售量持续增加所致;另一方面系与Prolium达成授权许可的首付款确认相关收入所致。诺诚健华2025年1-3月公司核心产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.